Prosthetic Heart Valve Market Size and Share - Growth Analysis Report and Forecast Trends 2026-2030

Prosthetic heart valves are implantable devices used in surgical and transcatheter procedures to treat stenosis or regurgitation of the aortic, mitral, pulmonary, or tricuspid valves. The global market is currently valued at approximately USD 11.9 billion in 2025, with multiple analyst forecasts placing it in the USD 25-28 billion range by the early 2030s. Procedure volumes are shifting away from open surgical aortic valve replacement (SAVR) and toward transcatheter approaches, particularly TAVR, which now accounts for the majority of aortic valve interventions in many high-income health systems.

• •2025 market value approximately USD 11.9 billion, with projected 2032-2034 values between USD 25 billion and USD 28 billion.
• •TAVR has become the dominant approach for aortic valve replacement in older and higher-risk patients across North America, Western Europe, and parts of Asia-Pacific.
• •Biological (tissue) valves continue to outpace mechanical valves in unit volume due to lower anticoagulation burden.

The principal growth driver is the rising global burden of valvular heart disease, particularly calcific aortic stenosis and mitral regurgitation, which scale steeply with population age. The second major engine is the clinical and commercial expansion of transcatheter therapies, which have moved from inoperable and high-risk patients into intermediate- and lower-risk cohorts. A third contributor is improving reimbursement, hospital infrastructure, and physician training in Asia-Pacific and Latin America, which is broadening the addressable patient pool.

• •Population aging and higher diagnosis rates of aortic stenosis in patients aged 65 and above are expanding the treated prevalence base.
• •TAVR indications have been progressively expanded following favorable outcomes in intermediate and low-risk trials.
• •Expanding reimbursement coverage for transcatheter valves in China, India, Brazil, and the Gulf states is opening new revenue pools.

By product, the market splits into mechanical valves, tissue (bioprosthetic) valves, and transcatheter valves, with tissue and transcatheter devices together representing the majority of revenue. By procedure, transcatheter replacement is the fastest-growing segment while surgical replacement remains sizeable in younger patients and emerging markets. Geographically, North America holds the leading share on the strength of TAVR adoption, followed by Europe, while Asia-Pacific is the fastest-growing region.

• •Tissue and transcatheter valves together account for the majority of 2025 revenue, while mechanical valves retain a smaller, price-sensitive niche.
• •North America leads in revenue share, Europe follows, and Asia-Pacific is the fastest-growing region through 2030.
• •The aortic valve segment is the largest by indication, with mitral and tricuspid devices representing smaller but faster-growing opportunities.

What are the recent trends and outlook?

The medium-term outlook is shaped by the continued migration of valve replacement from surgery to catheter-based procedures, with mitral and tricuspid transcatheter therapies representing the next major frontier. Durability of bioprosthetic and transcatheter valves in younger patients, longer-term clinical data, and value-based reimbursement models will increasingly influence adoption. Over the forecast horizon, the market is expected to sustain double-digit growth, propelled by TAVR expansion into low-risk and younger cohorts and by accelerated access in emerging economies.

• •Transcatheter mitral and tricuspid repair and replacement systems are emerging as the next high-growth frontier beyond TAVR.
• •Valve durability data and lifetime management strategies for younger TAVR recipients are becoming central to clinical decision-making.
• •Over the forecast period, the market is projected to grow at a CAGR of roughly 11-12%, reaching approximately USD 25-28 billion by the early 2030s.